JP7134868B2 - 発現強化座位の使用に基づく抗体を作製するための組成物および方法 - Google Patents

発現強化座位の使用に基づく抗体を作製するための組成物および方法 Download PDF

Info

Publication number
JP7134868B2
JP7134868B2 JP2018552822A JP2018552822A JP7134868B2 JP 7134868 B2 JP7134868 B2 JP 7134868B2 JP 2018552822 A JP2018552822 A JP 2018552822A JP 2018552822 A JP2018552822 A JP 2018552822A JP 7134868 B2 JP7134868 B2 JP 7134868B2
Authority
JP
Japan
Prior art keywords
nucleic acid
rrs
nucleotide sequence
hcf
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514358A (ja
JP2019514358A5 (enExample
Inventor
ロバート バブ，
ダリャ ブラコフ，
ガン チェン，
ジェイムズ ピー． ファンデル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2019514358A publication Critical patent/JP2019514358A/ja
Publication of JP2019514358A5 publication Critical patent/JP2019514358A5/ja
Priority to JP2022137796A priority Critical patent/JP7546015B2/ja
Application granted granted Critical
Publication of JP7134868B2 publication Critical patent/JP7134868B2/ja
Priority to JP2024144352A priority patent/JP7789143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2018552822A 2016-04-20 2017-04-20 発現強化座位の使用に基づく抗体を作製するための組成物および方法 Active JP7134868B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022137796A JP7546015B2 (ja) 2016-04-20 2022-08-31 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP2024144352A JP7789143B2 (ja) 2016-04-20 2024-08-26 発現強化座位の使用に基づく抗体を作製するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20
US62/325,385 2016-04-20
PCT/US2017/028552 WO2017184831A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022137796A Division JP7546015B2 (ja) 2016-04-20 2022-08-31 発現強化座位の使用に基づく抗体を作製するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019514358A JP2019514358A (ja) 2019-06-06
JP2019514358A5 JP2019514358A5 (enExample) 2020-05-28
JP7134868B2 true JP7134868B2 (ja) 2022-09-12

Family

ID=58701850

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552822A Active JP7134868B2 (ja) 2016-04-20 2017-04-20 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP2022137796A Active JP7546015B2 (ja) 2016-04-20 2022-08-31 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP2024144352A Active JP7789143B2 (ja) 2016-04-20 2024-08-26 発現強化座位の使用に基づく抗体を作製するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022137796A Active JP7546015B2 (ja) 2016-04-20 2022-08-31 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP2024144352A Active JP7789143B2 (ja) 2016-04-20 2024-08-26 発現強化座位の使用に基づく抗体を作製するための組成物および方法

Country Status (15)

Country Link
US (2) US11530277B2 (enExample)
EP (1) EP3445780A1 (enExample)
JP (3) JP7134868B2 (enExample)
KR (2) KR102474757B1 (enExample)
CN (2) CN109071633B (enExample)
AR (1) AR108295A1 (enExample)
AU (2) AU2017253240B2 (enExample)
BR (1) BR112018071285A2 (enExample)
CA (1) CA3015371A1 (enExample)
EA (1) EA201892137A1 (enExample)
IL (2) IL262268B2 (enExample)
MX (2) MX2018012866A (enExample)
SG (2) SG10202010156XA (enExample)
TW (1) TW201803981A (enExample)
WO (1) WO2017184831A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
WO2020034097A1 (en) 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN113631711B (zh) * 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
KR20210134932A (ko) * 2019-03-29 2021-11-11 에프. 호프만-라 로슈 아게 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 FcRn 발현 세포를 생성하는 방법
EP3950938A4 (en) 2019-04-02 2023-01-18 Chugai Seiyaku Kabushiki Kaisha PROCEDURE FOR INTRODUCING A TARGET-SPECIFIC ALIEN
BR112021025425A2 (pt) * 2019-06-19 2022-02-01 Hoffmann La Roche Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
CA3140323A1 (en) * 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
MX2021015648A (es) 2019-06-19 2022-02-03 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida.
KR20220010019A (ko) * 2019-06-19 2022-01-25 에프. 호프만-라 로슈 아게 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 2가 이중특이성 항체 발현 세포를 생성하는 방법
CA3140287A1 (en) * 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020308002A1 (en) * 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
CN115335517A (zh) * 2020-01-10 2022-11-11 豪夫迈·罗氏有限公司 用于从短片段组装大核酸的方法
EP4453227A1 (en) * 2021-12-22 2024-10-30 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
CN119955730A (zh) * 2023-11-08 2025-05-09 深圳太力生物技术有限责任公司 一种细胞株及其制备方法与应用
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2009539349A (ja) 2006-06-02 2009-11-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP2012531439A (ja) 2009-06-26 2012-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2016507525A (ja) 2013-02-01 2016-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ定常領域を含む抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
KR100781481B1 (ko) 2000-08-07 2007-12-03 세로노 제네틱스 인스티튜트 에스.에이. 정신분열증 관련된 유전자와 단백질
GB0209884D0 (en) 2002-04-30 2002-06-05 Ares Trading Sa Proteins
AU2003237259B2 (en) 2002-05-29 2008-01-24 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2504595A1 (en) 2002-11-14 2004-06-03 Lynne Krummen Intron fusion construct and method of using for selecting high-expressing production cell lines
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2008079943A2 (en) 2006-12-21 2008-07-03 Smithkline Beecham Corporation Novel methods
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017005306A (es) * 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539349A (ja) 2006-06-02 2009-11-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2012531439A (ja) 2009-06-26 2012-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2016507525A (ja) 2013-02-01 2016-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ定常領域を含む抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biotechnol. Prog. (2015) Vol.31, No.6, pp.1645-1656

Also Published As

Publication number Publication date
MX2024014381A (es) 2024-12-06
EP3445780A1 (en) 2019-02-27
US20230322956A1 (en) 2023-10-12
TW201803981A (zh) 2018-02-01
SG10202010156XA (en) 2020-11-27
JP7789143B2 (ja) 2025-12-19
AU2017253240A1 (en) 2018-09-20
US12503520B2 (en) 2025-12-23
AU2024220126A1 (en) 2024-10-17
IL309065A (en) 2024-02-01
IL262268B2 (en) 2024-05-01
CN109071633A (zh) 2018-12-21
CN109071633B (zh) 2022-11-18
SG11201807881VA (en) 2018-10-30
IL262268A (en) 2018-11-29
JP2019514358A (ja) 2019-06-06
AR108295A1 (es) 2018-08-08
IL262268B1 (en) 2024-01-01
JP2024164196A (ja) 2024-11-26
KR20210135340A (ko) 2021-11-12
KR102474757B1 (ko) 2022-12-07
WO2017184831A1 (en) 2017-10-26
US11530277B2 (en) 2022-12-20
KR20180134894A (ko) 2018-12-19
IL309065B1 (en) 2026-03-01
EA201892137A1 (ru) 2019-03-29
AU2017253240B2 (en) 2024-07-04
JP7546015B2 (ja) 2024-09-05
CA3015371A1 (en) 2017-10-26
JP2022164824A (ja) 2022-10-27
BR112018071285A2 (pt) 2019-02-12
CN116004544A (zh) 2023-04-25
US20190263937A1 (en) 2019-08-29
MX2018012866A (es) 2019-03-11

Similar Documents

Publication Publication Date Title
JP7546015B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7781128B2 (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA052803B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA051643B1 (ru) Композиции и способы получения антител, основанные на применении локуса, обеспечивающего повышенную экспрессию
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220831

R150 Certificate of patent or registration of utility model

Ref document number: 7134868

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150